Severe acute arterial insufficiency linked to ergotism
Abstract
Ergotism is a rare but potentially lethal clinical syndrome linked to acute or chronic poisoning with the use of ergot alkaloids in the treatment of migraine. It is characterized by a severe generalized vasospasm that can generate peripheral or visceral ischemia and lead to multiple organ dysfunction and death. There are numerous drugs of hepatic metabolism that can alter the metabolism of ergotamine and can reach toxic concentrations even at low doses. We present the case of a patient infected with human immunodeficiency virus under antiretroviral treatment that included protease inhibitors and who had self-administered with ergotamine. The patient subsequently presented motor sensory deficit symptoms of upper and lower limbs, accompanied by elements of severe distal hypoperfusion. Arterial Doppler was requested, which showed vasospasm of the arterial axis of the limbs. A diagnosis of ergotism secondary to the ergotamine-ritonavir association was made, entering intensive care. Treatment was started based on suspension of both drugs, arterial vasodilatation with nitroprusside and antiaggregation with acetylsalicylic acid. In relation to this case, we present a review of the ergotamine toxicity mechanism, its pharmacological interactions, as well as the diagnosis and treatment available for this pathology.
References
(1) Pastur L, Milano Gil A. Ergotamina e inhibidores de la proteasa, impacto clínico de las interacciones farmacológicas: presentación de dos casos. Actual SIDA 2014; 20(5):1-4.
(2) Jason Chu. Antimigrainemedications. En: Nelson L, Lewin N, Howland M, Hoffman R, Goldfrank L. Goldfrank's toxicologic emergencies. 9 ed. New York: McGraw-Hill, 2011:763-70.
(3) Cisneros J, Jauregui L, Rojas G. Insuficiencia arterial aguda por ergotismo. An Med (Mex) 2008; 53(4):202-10.
(4) Sanders-Bush E, Mayer SE. Agonistas y antagonistas del receptor de 5-HT. En: Brunton LL, Lazo JS, Parker KL. Goodman y Gilman: las bases farmacológicas de la terapéutica. 11 ed. México: McGraw-Hill; 2007:305-11.
(5) Ayarragaray JE. Ergotism: a change of persepective. Ann Vasc Surg 2014; 28(1):265-8.
(6) Finn B, Vadalá S, Meraldi A, Bruetman J, Martínez J, Young P. Ergotismo y HIV. Medicina (B. Aires) 2013; 73(4):346-8.
(7) Enríquez E, Rangel A, Velasco C, Basave M, López R. Ergotismo por autolimitación. Arch Inst Cardiol Mex 2000; 70(6):603-8.
(8) Liegl C, McGrath M. Ergotism: case report and review of the literature. Int J Angiol 2016; 25(5):e8-11.
(9) Cairols M, Giménez A, Sieyro F, Miralles M. Intoxicación ergotamínica: dos casos de isquemia periférica. Angiología 1991; 43(4):148-52.
(10) Acle S, Roca F, Vacarezza M, Álvarez A. Ergotismo secundario a la asociación ergotamina-ritanivir: a propósito de 3 casos. Rev Méd Chile 2011; 139(12):1597-600.
(11) Dilmé J, Barreiro J, Yeste M, Escudero J, Llagoslera S, Mestes J, et al. Ergotismo revisión de bibliografía. Angiología 2003; 55(4):311-21.